Comment from PCCA and NCPA
AnonymousSupportTrade association
Summary: The Pharmaceutical Compounding Association of America (PCCA) and the National Community Pharmacy Association (NCPA) are advocating for the inclusion of glutathione on the 503A Bulk Drug Substances list. They provide clinical evidence and data on its use in treating cystic fibrosis and chemotherapy-induced neuropathy to support its status as a viable active pharmaceutical ingredient for compounding.
This comment is in response to FDA's request for clarification for the nomination of glutathione to the 503A Bulk Drug Substances List.